Metformin and cancer

European Journal of Pharmacology

Volumn 705, Issue 1-3, 2013, Pages 96-108

  Rizos, Christos V ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cancer; Diabetes; Metformin; Mortality; Neoplasm; Pleiotropic effects

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PACLITAXEL; PLACEBO; SULFONYLUREA DERIVATIVE; TRASTUZUMAB;

ANTIDIABETIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CHEMORADIOTHERAPY; COLORECTAL CANCER; COLORECTAL POLYP; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG POTENTIATION; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS INHIBITION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; REVIEW; SIDE EFFECT; TUMOR REGRESSION; VITAMIN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84875303678     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.02.038     Document Type: Review

References (147)

1. R. Abe, and S. Yamagishi AGE-RAGE system and carcinogenesis Curr. Pharm. Des. 14 2008 940 945
2. C. Algire, O. Moiseeva, X. Deschenes-Simard, L. Amrein, L. Petruccelli, E. Birman, B. Viollet, G. Ferbeyre, and M.N. Pollak Metformin reduces endogenous reactive oxygen species and associated DNA damage Cancer Prev. Res. (Phila) 5 2012 536 543
3. H. Ashinuma, Y. Takiguchi, S. Kitazono, M. Kitazono-Saitoh, A. Kitamura, T. Chiba, Y. Tada, K. Kurosu, E. Sakaida, I. Sekine, N. Tanabe, A. Iwama, O. Yokosuka, and K. Tatsumi Antiproliferative action of metformin in human lung cancer cell lines Oncol. Rep. 28 2012 8 14
4. L. Azoulay, S. Dell'Aniello, B. Gagnon, M. Pollak, and S. Suissa Metformin and the incidence of prostate cancer in patients with type 2 diabetes Cancer Epidemiol. Biomarkers Prev. 20 2011 337 344
5. B.B. Barone, H.C. Yeh, C.F. Snyder, K.S. Peairs, K.B. Stein, R.L. Derr, A.C. Wolff, and F.L. Brancati Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis JAMA-J. Am. Med. Assoc. 300 2008 2754 2764
6. B.B. Barone, H.C. Yeh, C.F. Snyder, K.S. Peairs, K.B. Stein, R.L. Derr, A.C. Wolff, and F.L. Brancati Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis Diabetes Care 33 2010 931 939
7. A. Belfiore, and R. Malaguarnera Insulin receptor and cancer Endocrinol. Relat. Cancer 18 2011 R125 R147
8. M. Betancourt-Albrecht, and G.R. Cunningham Hypogonadism and diabetes Int. J. Impotence Res. 15 Suppl 4 2003 S14 S20
9. K. Bhalla, B.J. Hwang, R.E. Dewi, W. Twaddel, O.G. Goloubeva, K.K. Wong, N.K. Saxena, S. Biswal, and G.D. Girnun Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis Cancer Prev. Res. (Phila) 5 2012 544 552
10. M. Bodmer, C. Becker, S.S. Jick, and C.R. Meier Metformin does not alter the risk of lung cancer: a case-control analysis Lung Cancer 78 2012 133 137
11. M. Bodmer, C. Becker, C. Meier, S.S. Jick, and C.R. Meier Use of metformin and the risk of ovarian cancer: a case-control analysis Gynecol. Oncol. 123 2011 200 204
12. M. Bodmer, C. Becker, C. Meier, S.S. Jick, and C.R. Meier Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis Cancer Epidemiol. Biomarkers Prev. 21 2012 280 286
13. M. Bodmer, C. Meier, S. Krahenbuhl, S.S. Jick, and C.R. Meier Long-term metformin use is associated with decreased risk of breast cancer Diabetes Care 33 2010 1304 1308
14. B. Bonanni, M. Puntoni, M. Cazzaniga, G. Pruneri, D. Serrano, A. Guerrieri-Gonzaga, A. Gennari, M.S. Trabacca, V. Galimberti, P. Veronesi, H. Johansson, V. Aristarco, F. Bassi, A. Luini, M. Lazzeroni, C. Varricchio, G. Viale, P. Bruzzi, and A. Decensi Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial J. Clin. Oncol. 30 2012 2593 2600
15. S.L. Bowker, S.R. Majumdar, P. Veugelers, and J.A. Johnson Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 2006 254 258
16. S.L. Bowker, K. Richardson, C.A. Marra, and J.A. Johnson Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women Diabetes Care 34 2011 2542 2544
17. P. Boyle, M. Boniol, A. Koechlin, C. Robertson, F. Valentini, K. Coppens, L.L. Fairley, T. Zheng, Y. Zhang, M. Pasterk, M. Smans, M.P. Curado, P. Mullie, S. Gandini, M. Bota, G.B. Bolli, J. Rosenstock, and P. Autier Diabetes and breast cancer risk: a meta-analysis Br. J. Cancer 107 2012 1608 1617
18. C.D. Byrne Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management Diabetic Med. 29 2012 1098 1107
19. L.A. Cantrell, C. Zhou, A. Mendivil, K.M. Malloy, P.A. Gehrig, and V.L. Bae-Jump Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy Gynecol. Oncol. 116 2010 92 98
20. S. Caronia, K. Taylor, L. Pagliaro, C. Carr, U. Palazzo, J. Petrik, S. O'Rahilly, S. Shore, B.D. Tom, and G.J. Alexander Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection Hepatology 30 1999 1059 1063
21. B. Carstensen, D.R. Witte, and S. Friis Cancer occurrence in Danish diabetic patients: duration and insulin effects Diabetologia 55 2012 948 958
22. H.F. Chen, C.Y. Li, P. Chen, T.T. See, and H.Y. Lee Seroprevalence of hepatitis B and C in type 2 diabetic patients J. Chin. Med. Assoc. 69 2006 146 152
23. R.T. Chlebowski, A. McTiernan, J. Wactawski-Wende, J.E. Manson, A.K. Aragaki, T. Rohan, E. Ipp, V.G. Kaklamani, M. Vitolins, R. Wallace, M. Gunter, L.S. Phillips, H. Strickler, K. Margolis, and D.M. Euhus Diabetes, metformin, and breast cancer in postmenopausal women J. Clin. Oncol. 30 2012 2844 2852
24. T.A. Chowdhury Diabetes and cancer QJM 103 2010 905 915
25. Y.W. Chung, D.S. Han, K.H. Park, C.S. Eun, K.S. Yoo, and C.K. Park Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea Dis. Colon Rectum 51 2008 593 597
26. N.F. Col, L. Ochs, V. Springmann, A.K. Aragaki, and R.T. Chlebowski Metformin and breast cancer risk: a meta-analysis and critical literature review Breast Cancer Res. Treat. 135 2012 639 646
27. C.C. Cowie, K.F. Rust, D.D. Byrd-Holt, M.S. Eberhardt, K.M. Flegal, M.M. Engelgau, S.H. Saydah, D.E. Williams, L.S. Geiss, and E.W. Gregg Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002 Diabetes Care 29 2006 1263 1268
28. S. Cufi, B. Corominas-Faja, A. Vazquez-Martin, C. Oliveras-Ferraros, J. Dorca, J. Bosch-Barrera, B. Martin-Castillo, and J.A. Menendez Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts Oncotarget 3 2012 395 398
29. C.J. Currie, C.D. Poole, and E.A. Gale The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777
30. C.J. Currie, C.D. Poole, S. Jenkins-Jones, E.A. Gale, J.A. Johnson, and C.L. Morgan Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival Diabetes Care 35 2012 299 304
31. K. Cusi, A. Consoli, and R.A. DeFronzo Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus J. Clin. Endocrinol. Metab. 81 1996 4059 4067
32. K. Cusi, K. Maezono, A. Osman, M. Pendergrass, M.E. Patti, T. Pratipanawatr, R.A. DeFronzo, C.R. Kahn, and L.J. Mandarino Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle J. Clin. Invest. 105 2000 311 320
33. J. Dancey mTOR signaling and drug development in cancer Nat. Rev. Clin. Oncol. 7 2010 209 219
34. S.P. Davies, N.R. Helps, P.T. Cohen, and D.G. Hardie 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC FEBS Lett. 377 1995 421 425
35. J.A. Davila, R.O. Morgan, Y. Shaib, K.A. McGlynn, and H.B. El-Serag Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study Gut 54 2005 533 539
36. R.A. DeFronzo, and A.M. Goodman Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group N. Engl. J. Med. 333 1995 541 549
37. Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study Diabetes Care 35 2012 731 737
38. V. Donadon, M. Balbi, M.D. Mas, P. Casarin, and G. Zanette Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease Liver Int. 30 2010 750 758
39. L. Dong, Q. Zhou, Z. Zhang, Y. Zhu, T. Duan, and Y. Feng Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression J. Obstet. Gynaecol. Res. 38 2012 1077 1085
40. R.J. Dowling, S. Niraula, V. Stambolic, and P.J. Goodwin Metformin in cancer: translational challenges J. Mol. Endocrinol. 48 2012 R31 R43
41. R.J. Dowling, M. Zakikhani, I.G. Fantus, M. Pollak, and N. Sonenberg Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res. 67 2007 10804 10812
42. M.Y. El-Mir, V. Nogueira, E. Fontaine, N. Averet, M. Rigoulet, and X. Leverve Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I J. Biol. Chem. 275 2000 223 228
43. H.B. El-Serag, H. Hampel, and F. Javadi The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence Clin. Gastroenterol. Hepatol. 4 2006 369 380
44. J.A. Engelman, and L.C. Cantley Chemoprevention meets glucose control Cancer Prev. Res. (Phila) 3 2010 1049 1052
45. J. Everhart, and D. Wright Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis JAMA: J. Am. Med. Assoc. 273 1995 1605 1609
46. M. Foretz, S. Hebrard, J. Leclerc, E. Zarrinpashneh, M. Soty, G. Mithieux, K. Sakamoto, F. Andreelli, and B. Viollet Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state J. Clin. Invest. 120 2010 2355 2369
47. F. Frasca, G. Pandini, L. Sciacca, V. Pezzino, S. Squatrito, A. Belfiore, and R. Vigneri The role of insulin receptors and IGF-I receptors in cancer and other diseases Arch. Physiol. Biochem. 114 2008 23 37
48. E. Friberg, N. Orsini, C.S. Mantzoros, and A. Wolk Diabetes mellitus and risk of endometrial cancer: a meta-analysis Diabetologia 50 2007 1365 1374
49. C.R. Garrett, H.M. Hassabo, N.A. Bhadkamkar, S. Wen, V. Baladandayuthapani, B.K. Kee, C. Eng, and M.M. Hassan Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer Br. J. Cancer 106 2012 1374 1378
50. N. Geraldine, A. Marc, T. Carla, M. Chantal, B. Stefaan, W. Welcome, and B. Frank Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting Diabetes Res. Clin. Pract. 97 2012 331 336
51. E. Giovannucci, D.M. Harlan, M.C. Archer, R.M. Bergenstal, S.M. Gapstur, L.A. Habel, M. Pollak, J.G. Regensteiner, and D. Yee Diabetes and cancer: a consensus report CA Cancer J. Clin. 60 2010 207 221
52. A.M. Gonzalez-Angulo, and F. Meric-Bernstam Metformin: a therapeutic opportunity in breast cancer Clin. Cancer Res. 16 2010 1695 1700
53. P.J. Goodwin, V. Stambolic, J. Lemieux, B.E. Chen, W.R. Parulekar, K.A. Gelmon, D.L. Hershman, T.J. Hobday, J.A. Ligibel, I.A. Mayer, K.I. Pritchard, T.J. Whelan, P. Rastogi, and L.E. Shepherd Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents Breast Cancer Res. Treat. 126 2011 215 220
54. A.S. Green, N. Chapuis, T.T. Maciel, L. Willems, M. Lambert, C. Arnoult, O. Boyer, V. Bardet, S. Park, M. Foretz, B. Viollet, N. Ifrah, F. Dreyfus, O. Hermine, I.C. Moura, C. Lacombe, P. Mayeux, D. Bouscary, and J. Tamburini The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation Blood 116 2010 4262 4273
55. A. Guppy, M. Jamal-Hanjani, and L. Pickering Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer Future Oncol. 7 2011 727 736
56. S. Hadad, T. Iwamoto, L. Jordan, C. Purdie, S. Bray, L. Baker, G. Jellema, S. Deharo, D.G. Hardie, L. Pusztai, S. Moulder-Thompson, J.A. Dewar, and A.M. Thompson Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial Breast Cancer Res. Treat. 128 2011 783 794
57. R.K. Hanna, C. Zhou, K.M. Malloy, L. Sun, Y. Zhong, P.A. Gehrig, and V.L. Bae-Jump Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway Gynecol. Oncol. 125 2012 458 469
58. D.G. Hardie The AMP-activated protein kinase pathway - new players upstream and downstream J. Cell Sci. 117 2004 5479 5487
59. M.I. Harris, K.M. Flegal, C.C. Cowie, M.S. Eberhardt, D.E. Goldstein, R.R. Little, H.M. Wiedmeyer, and D.D. Byrd-Holt Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994 Diabetes Care 21 1998 518 524
60. N.S. Harris, and W.E. Winter The chemical pathology of insulin resistance and the metabolic syndrome MLO: Med. Lab. Obs. 36 20 2004 22 25
61. M.M. Hassan, S.A. Curley, D. Li, A. Kaseb, M. Davila, E.K. Abdalla, M. Javle, D.M. Moghazy, R.D. Lozano, J.L. Abbruzzese, and J.N. Vauthey Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma Cancer 116 2010 1938 1946
62. S.A. Hawley, M. Davison, A. Woods, S.P. Davies, R.K. Beri, D. Carling, and D.G. Hardie Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase J. Biol. Chem. 271 1996 27879 27887
63. X. He, F.J. Esteva, J. Ensor, G.N. Hortobagyi, M.H. Lee, and S.C. Yeung Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer Ann. Oncol. 23 2012 1771 1780
64. T. Higurashi, H. Takahashi, H. Endo, K. Hosono, E. Yamada, H. Ohkubo, E. Sakai, T. Uchiyama, Y. Hata, N. Fujisawa, S. Uchiyama, A. Ezuka, H. Nagase, T. Kessoku, N. Matsuhashi, S. Yamanaka, Y. Inayama, S. Morita, and A. Nakajima Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial BMC Cancer 12 2012 118
65. P.M. Ho, P.N. Peterson, and F.A. Masoudi Evaluating the evidence: is there a rigid hierarchy? Circulation 118 2008 1675 1684
66. K. Hosono, H. Endo, H. Takahashi, M. Sugiyama, E. Sakai, T. Uchiyama, K. Suzuki, H. Iida, Y. Sakamoto, K. Yoneda, T. Koide, C. Tokoro, Y. Abe, M. Inamori, H. Nakagama, and A. Nakajima Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev. Res. (Phila) 3 2010 1077 1083
67. L. Huai, C. Wang, C. Zhang, Q. Li, Y. Chen, Y. Jia, Y. Li, H. Xing, Z. Tian, Q. Rao, M. Wang, and J. Wang Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway Biochem. Biophys. Res. Commun. 422 2012 398 404
68. R.T. Hurst, and R.W. Lee Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management Ann. Intern. Med. 139 2003 824 834
69. T. Ikeda, K. Iwata, and H. Murakami Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine Biochem. Pharmacol. 59 2000 887 890
70. D. Iliopoulos, H.A. Hirsch, and K. Struhl Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types Cancer Res. 71 2011 3196 3201
71. Z.Y. Jiang, Y.W. Lin, A. Clemont, E.P. Feener, K.D. Hein, M. Igarashi, T. Yamauchi, M.F. White, and G.L. King Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats J. Clin. Invest. 104 1999 447 457
72. A. Kalender, A. Selvaraj, S.Y. Kim, P. Gulati, S. Brule, B. Viollet, B.E. Kemp, N. Bardeesy, P. Dennis, J.J. Schlager, A. Marette, S.C. Kozma, and G. Thomas Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner Cell Metab. 11 2010 390 401
73. J.S. Kasper, and E. Giovannucci A meta-analysis of diabetes mellitus and the risk of prostate cancer Cancer Epidemiol. Biomarkers Prev. 15 2006 2056 2062
74. K. Kato, J. Gong, H. Iwama, A. Kitanaka, J. Tani, H. Miyoshi, K. Nomura, S. Mimura, M. Kobayashi, Y. Aritomo, H. Kobara, H. Mori, T. Himoto, K. Okano, Y. Suzuki, K. Murao, and T. Masaki The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo Mol. Cancer Ther. 11 2012 549 560
75. H. King, R.E. Aubert, and W.H. Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
76. J. Klubo-Gwiezdzinska, K. Jensen, J. Costello, A. Patel, V. Hoperia, A. Bauer, K.D. Burman, L. Wartofsky, and V. Vasko Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells Endocrinol. Relat. Cancer 19 2012 447 456
77. H.J. Klumpen, J.H. Beijnen, H. Gurney, and J.H. Schellens Inhibitors of mTOR Oncologist 15 2010 1262 1269
78. W.C. Knowler, S.E. Fowler, R.F. Hamman, C.A. Christophi, H.J. Hoffman, A.T. Brenneman, J.O. Brown-Friday, R. Goldberg, E. Venditti, and D.M. Nathan 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 374 2009 1677 1686
79. S.W. Lai, P.C. Chen, K.F. Liao, C.H. Muo, C.C. Lin, and F.C. Sung Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study Am. J. Gastroenterol. 107 2012 46 52
80. S.W. Lai, K.F. Liao, P.C. Chen, P.Y. Tsai, D.P. Hsieh, and C.C. Chen Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan Clin Lung Cancer 13 2012 143 148
81. G.W. Landman, N. Kleefstra, K.J. van Hateren, K.H. Groenier, R.O. Gans, and H.J. Bilo Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 Diabetes Care 33 2010 322 326
82. S.C. Larsson, N. Orsini, and A. Wolk Diabetes mellitus and risk of colorectal cancer: a meta-analysis J. Nat. Cancer Inst. 97 2005 1679 1687
83. S.C. Larsson, and A. Wolk Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies Diabetologia 54 2011 1013 1018
84. M.S. Lee, C.C. Hsu, M.L. Wahlqvist, H.N. Tsai, Y.H. Chang, and Y.C. Huang Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals BMC Cancer 11 2011 20
85. D.M. Lehman, C. Lorenzo, J. Hernandez, and C.P. Wang Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients Diabetes Care 35 2012 1002 1007
86. J.D. Lewis, A.M. Capra, N.S. Achacoso, A. Ferrara, T.R. Levin, C.P. Quesenberry Jr., and L.A. Habel Medical therapy for diabetes is associated with increased use of lower endoscopy Pharmacoepidemiol. Drug Saf. 16 2007 1195 1202
87. S. Liao, J. Li, W. Wei, L. Wang, Y. Zhang, C. Wang, and S. Sun Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature Asian Pac. J. Cancer Prev. 12 2011 1061 1065
88. G. Libby, L.A. Donnelly, P.T. Donnan, D.R. Alessi, A.D. Morris, and J.M. Evans New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
89. L.L. Lipscombe, P.J. Goodwin, B. Zinman, J.R. McLaughlin, and J.E. Hux The impact of diabetes on survival following breast cancer Breast Cancer Res. Treat. 109 2008 389 395
90. L.L. Lipscombe, and J.E. Hux Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study Lancet 369 2007 750 756
91. H. Liu, C. Scholz, C. Zang, J.H. Schefe, P. Habbel, A.C. Regierer, C.O. Schulz, K. Possinger, and J. Eucker Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro Anticancer Res. 32 2012 1627 1637
92. A. Lonardo, L.E. Adinolfi, S. Petta, A. Craxi, and P. Loria Hepatitis C and diabetes: the inevitable coincidence? Expert Rev. Anti Infect. Ther. 7 2009 293 308
93. J. Ma, H. Li, E. Giovannucci, L. Mucci, W. Qiu, P.L. Nguyen, J.M. Gaziano, M. Pollak, and M.J. Stampfer Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis Lancet Oncol. 9 2008 1039 1047
94. T. MacKenzie, M.S. Zens, A. Ferrara, A. Schned, and M.R. Karagas Diabetes and risk of bladder cancer: evidence from a case-control study in New England Cancer 117 2011 1552 1556
95. P.J. Mazzone, H. Rai, M. Beukemann, M. Xu, A.K. Jain, and M. Sasidhar The effect of metformin and thiazolidinedione use on lung cancer in diabetics BMC Cancer 12 2012 410
96. R.M. Memmott, and P.A. Dennis LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin J. Clin. Oncol. 27 2009 e226; author reply e227
97. J.A. Menendez, and R. Lupu Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis Nat. Rev. Cancer 7 2007 763 777
98. J.A. Meyerhardt, P.J. Catalano, D.G. Haller, R.J. Mayer, J.S. Macdonald, A.B. Benson 3rd, and C.S. Fuchs Impact of diabetes mellitus on outcomes in patients with colon cancer J. Clin. Oncol. 21 2003 433 440
99. K.B. Michels, C.G. Solomon, F.B. Hu, B.A. Rosner, S.E. Hankinson, G.A. Colditz, and J.E. Manson Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study Diabetes Care 26 2003 1752 1758
100. Y. Miyazaki, M. Matsuda, and R.A. DeFronzo Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes Diabetes Care 25 2002 517 523
101. S. Niraula, R.J. Dowling, M. Ennis, M.C. Chang, S.J. Done, N. Hood, J. Escallon, W.L. Leong, D.R. McCready, M. Reedijk, V. Stambolic, and P.J. Goodwin Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study Breast Cancer Res. Treat. 135 2012 821 830
102. G. Nkontchou, E. Cosson, M. Aout, A. Mahmoudi, V. Bourcier, I. Charif, N. Ganne-Carrie, V. Grando-Lemaire, E. Vicaut, J.C. Trinchet, and M. Beaugrand Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients J. Clin. Endocrinol. Metab. 96 2011 2601 2608
103. J.H. Noble Jr. Meta-analysis: methods, strengths, weaknesses, and political uses J. Lab. Clin. Med. 147 2006 7 20
104. H. Noto, A. Goto, T. Tsujimoto, and M. Noda Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis PLoS One 7 2012 e33411
105. T. Okumura Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs J. Gastroenterol. 45 2010 1097 1102
106. A. Pandey, V. Forte, M. Abdallah, A. Alickaj, S. Mahmud, S. Asad, and S.I. McFarlane Diabetes mellitus and the risk of cancer Minerva Endocrinol. 36 2011 187 209
107. P. Pisani Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies Arch. Physiol. Biochem. 114 2008 63 70
108. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat. Rev. Cancer 8 2008 915 928
109. M. Pollak The insulin and insulin-like growth factor receptor family in neoplasia: an update Nat. Rev. Cancer 12 2012 159 169
110. M.N. Pollak Investigating metformin for cancer prevention and treatment: the end of the beginning Cancer Discov. 2 2012 778 790
111. C. Postic, and J. Girard The role of the lipogenic pathway in the development of hepatic steatosis Diabetes Metab. 34 2008 643 648
112. Z. Qu, Y. Zhang, M. Liao, Y. Chen, J. Zhao, and Y. Pan In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 42 2012 922 933
113. R. Rattan, R.P. Graham, J.L. Maguire, S. Giri, and V. Shridhar Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo Neoplasia 13 2011 483 491
114. M.L. Reilly, S.F. Schillie, E. Smith, T. Poissant, C.W. Vonderwahl, K. Gerard, J. Baumgartner, L. Mercedes, K. Sweet, D. Muleta, D.J. Zaccaro, R.M. Klevens, and T.V. Murphy Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus J. Diabetes Sci. Technol. 6 2012 858 866
115. L.C. Richardson, and L.A. Pollack Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer Nat. Clin. Pract. Oncol. 2 2005 48 53
116. C.V. Rizos, M.S. Elisaf, D.P. Mikhailidis, and E.N. Liberopoulos How safe is the use of thiazolidinediones in clinical practice? Expert Opin. Drug Saf. 8 2009 15 32
117. C.V. Rizos, E.N. Liberopoulos, D.P. Mikhailidis, and M.S. Elisaf Pleiotropic effects of thiazolidinediones Expert Opin. Pharmacother. 9 2008 1087 1108
118. I.L. Romero, A. McCormick, K.A. McEwen, S. Park, T. Karrison, S.D. Yamada, S. Pannain, and E. Lengyel Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity Obstet. Gynecol. 119 2012 61 67
119. N.A. Roper, R.W. Bilous, W.F. Kelly, N.C. Unwin, and V.M. Connolly Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study BMJ 322 2001 1389 1393
120. R. Ruiter, L.E. Visser, M.P. van Herk-Sukel, J.W. Coebergh, H.R. Haak, P.H. Geelhoed-Duijvestijn, S.M. Straus, R.M. Herings, and B.H. Stricker Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study Diabetes Care 35 2012 119 124
121. N. Sadeghi, J.L. Abbruzzese, S.C. Yeung, M. Hassan, and D. Li Metformin use is associated with better survival of diabetic patients with pancreatic cancer Clin. Cancer Res. 18 2012 2905 2912
122. S.R. Salpeter, E. Greyber, G.A. Pasternak, and E.E. Salpeter Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst. Rev. 2010 CD002967
123. A.A. Samani, S. Yakar, D. LeRoith, and P. Brodt The role of the IGF system in cancer growth and metastasis: overview and recent insights Endocrinol. Rev. 28 2007 20 47
124. R.J. Shaw, N. Bardeesy, B.D. Manning, L. Lopez, M. Kosmatka, R.A. DePinho, and L.C. Cantley The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 6 2004 91 99
125. A. Sikka, M. Kaur, C. Agarwal, G. Deep, and R. Agarwal Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation Cell Cycle 11 2012 1374 1382
126. H.D. Skinner, M.R. McCurdy, A.E. Echeverria, S.H. Lin, J.W. Welsh, M.S. O'Reilly, W.L. Hofstetter, J.A. Ajani, R. Komaki, J.D. Cox, V.C. Sandulache, J.N. Myers, and T.M. Guerrero Metformin use and improved response to therapy in esophageal adenocarcinoma Acta Oncol. 2012 Epub ahead of print
127. B.B. Smiechowski, L. Azoulay, H. Yin, M.N. Pollak, and S. Suissa The use of metformin and the incidence of lung cancer in patients with type 2 diabetes Diabetes Care 2012 Epub ahead of print
128. C.W. Song, H. Lee, R.P. Dings, B. Williams, J. Powers, T.D. Santos, B.H. Choi, and H.J. Park Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells Sci. Rep. 2 2012 362
129. D. Soranna, L. Scotti, A. Zambon, C. Bosetti, G. Grassi, A. Catapano, C. La Vecchia, G. Mancia, and G. Corrao Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Oncologist 17 2012 813 822
130. R.J. Stevens, R. Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, R.P. Camisasca, F.L. Crowe, A.J. Farmer, S. Harrison, J.A. Hirst, P. Home, S.E. Kahn, J.H. McLellan, R. Perera, A. Pluddemann, A. Ramachandran, N.W. Roberts, P.W. Rose, A. Schweizer, G. Viberti, and R.R. Holman Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Diabetologia 55 2012 2593 2603
131. R.J. Stevens, R. Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, R.P. Camisasca, F.L. Crowe, A.J. Farmer, S. Harrison, J.A. Hirst, P. Home, S.E. Kahn, J.H. McLellan, R. Perera, A. Pluddemann, A. Ramachandran, N.W. Roberts, P.W. Rose, A. Schweizer, G. Viberti, and R.R. Holman Erratum to: cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Diabetologia 55 2012 3399 3400
132. S. Suissa, and L. Azoulay Metformin and the risk of cancer: time-related biases in observational studies Diabetes care 35 2012 2665 2673
133. B.K. Tan, R. Adya, J. Chen, H. Lehnert, L.J. Sant Cassia, and H.S. Randeva Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells J. Clin. Endocrinol. Metab. 96 2011 808 816
134. C.H. Tseng Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan Eur. J. Endocrinol. 167 2012 409 416
135. T.P. van Staa, D. Patel, A.M. Gallagher, and M.L. de Bruin Glucose-lowering agents and the patterns of risk for cancer: a study with the general practice research database and secondary care data Diabetologia 55 2012 654 665
136. P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, and R. Vigneri Diabetes and cancer Endocrinol. Relat. Cancer 16 2009 1103 1123
137. E. Walker, A.V. Hernandez, and M.W. Kattan Meta-analysis: its strengths and limitations Cleve. Clin. J. Med. 75 2008 431 439
138. S. Wei, J. Yang, S.L. Lee, S.K. Kulp, and C.S. Chen PPARgamma-independent antitumor effects of thiazolidinediones Cancer Lett. 276 2009 119 124
139. C. Wilcock, and C.J. Bailey Reconsideration of inhibitory effect of metformin on intestinal glucose absorption J. Pharm. Pharmacol. 43 1991 120 121
140. A.D. Wright, C.A. Cull, K.M. Macleod, and R.R. Holman Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73 J. Diabetes Complications 20 2006 395 401
141. J.L. Wright, and J.L. Stanford Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes Control 20 2009 1617 1622
142. N. Wu, C. Gu, H. Gu, H. Hu, Y. Han, and Q. Li Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153 Neoplasma 58 2011 482 490
143. P.J. Wysocki, and B. Wierusz-Wysocka Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin Expert Rev. Mol. Diagn. 10 2010 509 519
144. Y.X. Yang, S. Hennessy, and J.D. Lewis Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 127 2004 1044 1050
145. K.H. Yoon, J.H. Lee, J.W. Kim, J.H. Cho, Y.H. Choi, S.H. Ko, P. Zimmet, and H.Y. Son Epidemic obesity and type 2 diabetes in Asia Lancet 368 2006 1681 1688
146. Z.J. Zhang, Z.J. Zheng, H. Kan, Y. Song, W. Cui, G. Zhao, and K.E. Kip Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis Diabetes Care 34 2011 2323 2328
147. Z.J. Zhang, Z.J. Zheng, R. Shi, Q. Su, Q. Jiang, and K.E. Kip Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis J. Clin. Endocrinol. Metab. 97 2012 2347 2353